key: cord-0931618-8fg4bs12
authors: Yang, Haiyan; Xu, Jie; Liang, Xuan; Shi, Li; Wang, Yadong
title: Autoimmune diseases are independently associated with COVID-19 severity: Evidence based on adjusted effect estimates
date: 2020-12-28
journal: J Infect
DOI: 10.1016/j.jinf.2020.12.025
sha: 9bf958e0ed887c792fccc9c81c58eca3008891b6
doc_id: 931618
cord_uid: 8fg4bs12

nan

There have been several published articles reporting the association between autoimmune diseases and the risk of severity among patients with coronavirus disease 2019 (COVID-19). But the conclusions across studies are inconsistent. [1] [2] [3] [4] [5] [6] Recently, Liu et al. performed a meta-analysis based on six studies with 2091 cases published in Journal of Infection to investigate the association between autoimmune diseases and severe or dead COVID-19. 7 Their results demonstrated that autoimmune diseases were not significantly associated with severe or dead COVID-19 (odds ratio (OR) = 1.21, 95% confidence interval (CI): 0.58-2.50 for severity and OR = 1.31, 95% CI: 0.33-5.20 for mortality). 7 This is an extremely interesting paper. However, the number of included studies and sample sizes are limited. Up to now, several papers with large sample sizes on this topic are emerging. Therefore, it is required to clarify the association between autoimmune diseases and COVID-19 severity based on updated data.

To our knowledge, several factors such as age, gender and underlying disorders (hypertension, diabetes, chronic obstructive pulmonary disease, cerebrovascular disease, cardiovascular disease, chronic kidney disease and obesity, etc.) significantly affected the clinical outcomes of COVID-19. This suggests that these risk factors might modulate the association of autoimmune diseases with COVID-19 severity. To obtain a precise conclusion, this metaanalysis was carried out based on published studies reporting adjusted effect estimates, rather than those reporting un-adjusted effect estimates.

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement. International databases of PubMed, Web of Science and EMBASE were searched to identify potential studies up to December 12, 2020. The following keywords were used: "coronavirus disease 2019 , "COVID-19 , "SARS-CoV-2 , "autoimmune diseases", "rheumatic diseases", "inflammatory bowel disease", "psoriasis" and "systemic lupus erythematosus". Only peerreviewed articles published in English reporting adjusted effect estimates on the association between autoimmune diseases and COVID-19 severity (severe, critical and mortal outcomes) were eligibly included. Repeated articles, case reports, reviews, comments, protocols, errata, and articles without sufficient information were excluded.

Data were extracted by two independent authors (Jie Xu and Haiyan Yang) from each included study. Questions or disagreements were resolved by discussion or consultation with a third author (Yadong Wang). Baseline information extracted from the included literature includes author name, location, sample sizes, number of autoimmune diseases, types of autoimmune diseases, age, gender distribution, study design, adjusted effect estimates, adjusted risk factors and disease outcomes. All statistical analyses were conducted using Stata 12.1 software. Heterogeneity was tested using I 2 statistic. The pooled effects with 95% CI were estimated. Publication bias was examined by Begg's test and Egger's test. Sensitivity analysis was performed to assess the stability of results. The level of significance was set at P < 0.05.

A total of thirteen studies 1 -6 , 8 -14 reporting 58,183 laboratoryconfirmed COVID-19 patients were included. The main characteristics of the selected studies are demonstrated in Table 1 . Our meta-analysis based on adjusted effect estimates revealed that COVID-19 patients with autoimmune diseases had a significantly increased risk of severity compared to those without autoimmune diseases (pooled effect = 1.19, 95% CI: 1.05-1.35) ( Fig. 1 A) . Sensitivity analysis exhibited that our results were stable and robust ( Fig. 1 B) . Publication bias was observed in Egger's test ( P = 0.017), but not in Begg's test ( P = 0.127, Fig. 1 C) . Subgroup analysis by location revealed that co-existing autoimmune diseases were significantly associated with an elevated risk of COVID-19 severity among USA population (pooled effect = 1.36, 95% CI: 1.02-1.81). This significant association was also observed in studies with mean age < 65 years old (pooled effect = 1.29, 95% CI: 1.04-1.60), studies with proportion of male ≥ 50% (pooled effect = 1.31, 95% CI: 1.06-1.62) and OR-reported studies (pooled effect = 1.21, 95% CI: 1.04-1.41).

Limitations should be acknowledged in this study. First, the included studies were mainly from Europe and USA, thus the conclusion should be cautiously extrapolated to other regions (such as Asia and Africa). Second, Begg's test showed no publication bias, but Egger's test revealed obvious publication bias. Thus, our findings should be confirmed in the future when more published studies are available. Third, subgroup analysis by the types of autoimmune diseases was not performed since most of the included studies did not report specific type of autoimmune diseases. Fourth, data on medications of autoimmune diseases were only available in four eligible studies, moreover the medications varied greatly across these studies, we did not further investigate the effect of medications on the association between autoimmune diseases and COVID-19 severity currently.

In conclusion, our study based on adjusted effect estimates demonstrates that autoimmune diseases are independently associated with an increased risk of COVID-19 severity, which provides new insight on the association between autoimmune diseases and COVID-19 severity. Therefore, special preventive measures should be taken to protect individuals with co-existing autoimmune diseases from exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and more clinical attention should be allocated to COVID-19 patients with autoimmune diseases to prevent disease progression. 

Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot

Risk of adverse outcomes in hospitalized patients with autoimmune disease and COVID-19: a matched cohort study from New York City

Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARSCoV2

Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study

Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2

Prognostic factors in Spanish COVID-19 patients: a case series from Barcelona

The association between severe or dead COVID-19 and autoimmune diseases: a systematic review and meta-analy